Tokyo-Based LTT Bio-Pharma Names New President
This article was originally published in PharmAsia News
Japanese regenerative medicine company, Tokyo-based LTT Bio-Pharma names Iwao Suzuki as its new president, effective June 25. Current president Toshimi Nishiyama becomes the board director. Suzuki joined LTT in March as director of operations and the appointment came as a surprise to many. Several executives recently resigned following an investment scandal involving a LTT subsidiary. LTT's founder Yutaka Mizushima also died recently. (Click here for more - Japanese language
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?